| Literature DB >> 35450356 |
Ruijia Zhang1, Feng Hong1, Min Zhao2, Xiaoying Cai1, Xueqin Jiang1, Neng Ye1, Kaiyue Su1, Na Li1, Minghai Tang1, Xu Ma1, Hengfan Ni3, Lun Wang1, Li Wan3, Lijuan Chen1, Wenshuang Wu4,5, Haoyu Ye1.
Abstract
The NLRP3 inflammasome has now emerged as one of the most appealing drug targets for many inflammation-related diseases. Velutone F, a natural NLPR3 inhibitor, identified in our previous study has been limited in application by its low in planta abundance, weak activity, and complicated synthetic routes. To address these needs, structural optimization of velutone F led to a series of novel NLRP3 inhibitors. Among them, compound 14c exerted remarkable inhibitory activity with an IC50 value in the nanomolar range (251.1 nM) and was approximately 5-fold more potent than velutone F. Moreover, the synthesis method of 14c was simple, easy to handle, and scalable. Compound 14c could suppress NLRP3 inflammasome activation by attenuating ASC speck formation. Most importantly, compound 14c reduced peritoneal neutrophil influx in mice and IL-1β in the spleen in the MSU-induced peritonitis in LPS-primed mouse model. Taken together, compound 14c is a prospective lead compound in the discovery of NLRP3 inflammasome inhibitors.Entities:
Year: 2022 PMID: 35450356 PMCID: PMC9014504 DOI: 10.1021/acsmedchemlett.1c00597
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632